Venus Remedies receives new marketing authorization for Docetaxel and Gemcitabine
Venus Remedies Limited has announced the successful receipt of new marketing authorizations for DOCETAXEL in concentrations of 160MG/8ML, 20MG/1 ML and 80MG/4ML(SingleVlal), as well as GEMCITABINE 1G from Malta, Europe.
These approvals signify the commitment to expanding its pharmaceutical portfolio and market presence. The company looks forward to leveraging these authorizations to enhance its global reach and contribute to the advancement of healthcare solutions.
Shivalik Rasayan submits USMDF for API 'Palbociclib’
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA. The Palbociclib is used for Breast Cancer and is under Patent in US till 2026.
